Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer

Diana C. Hsiung Stripp M.D.; Rosemarie Mick; Timothy C. Zhu; Richard Whittington; Debbie Smith R.N.; Andreea Dimofte; Jarod C. Finlay; Jeremy Miles; Theresa M. Busch; Daniel Shin; Alex Kachur; Zelig A. Tochner M.D.; S. Bruce Malkowicz; Eli Glatstein M.D.; Stephen M. Hahn

doi:10.1117/12.529181

14 June 2004 Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer

Diana C. Hsiung Stripp M.D., Rosemarie Mick, Timothy C. Zhu, Richard Whittington, Debbie Smith R.N., Andreea Dimofte, Jarod C. Finlay, Jeremy Miles, Theresa M. Busch, Daniel Shin, Alex Kachur, Zelig A. Tochner M.D., S. Bruce Malkowicz, Eli Glatstein M.D., Stephen M. Hahn

Author Affiliations +

Proceedings Volume 5315, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIII; (2004) https://doi.org/10.1117/12.529181
Event: Biomedical Optics 2004, 2004, San Jose, CA, United States

Abstract

Therapeutic options for patients with locally recurrent prostate cancer after treatment with radiation therapy are limited. An ongoing Phase I trial of interstitial photodynamic therapy (PDT) with the photosensitizer motexafin lutetium (MLu) was initiated in year 2000 for men with locally recurrent prostate cancer. The primary objective of this trial is to determine the maximally tolerated dose of motexafin lutetium-mediated PDT. Twelve men with biopsy-proven recurrent prostate cancer and no evidence of distant metastatic disease have been enrolled. Pre-treatment evaluation included an MRI of the prostate, bone scan, laboratory studies, cystoscopy, and transrectal ultrasound. Treatment plans were generated based upon the ultrasound findings. PDT dose was escalated by increasing the motexafin lutetium dose, increasing the 732 nm light dose, and decreasing the drug-light interval. Motexafin lutetium doses ranged from 0.5 to 2 mg/kg administered IV 3, 6, or 24 hours prior to 732 nm light delivery. The light dose measured in real time with in situ spherical detectors was 25-100 J/cm2 for all patients. Light was delivered through optical fibers inserted through a transperineal brachytherapy template in the operating room and optical property measurements were made before and after light therapy. Prostate biopsies were obtained before and after light delivery for spectrofluorometric measurements of photosensitizer uptake. Twelve patients have completed protocol treatment on eight dose levels without dose-limiting toxicity. Grade I PDT-related genitourinary symptoms were observed. One patient had Grade II urinary urgency that was urinary catheter-related. No rectal or other GI PDT-related toxicities were observed. Measurements of motexafin lutetium in prostate tissue demonstrated the presence of photosensitizer at all dose levels. Conclusions: Motexafin lutetium-mediated PDT designed to treat comprehensively the entired prostate gland has been well-tolerated at the doses studied to date.

Citation Download Citation

Diana C. Hsiung Stripp M.D., Rosemarie Mick, Timothy C. Zhu, Richard Whittington, Debbie Smith R.N., Andreea Dimofte, Jarod C. Finlay, Jeremy Miles, Theresa M. Busch, Daniel Shin, Alex Kachur, Zelig A. Tochner M.D., S. Bruce Malkowicz, Eli Glatstein M.D., and Stephen M. Hahn "Phase I trial of motexafin-lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer", Proc. SPIE 5315, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIII, (14 June 2004); https://doi.org/10.1117/12.529181

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available